Please login to the form below

Not currently logged in

Allergan subsidiary fined $125m for illegal marketing

Warner Chilcott toplead guilty with company’s president arrested

Allergan subsidiary Warner Chilcott will plead guilty to healthcare fraud and settle a case of illegal marketing for $125m.

Warner Chilcott USA has been charged with making illegal kickbacks to doctors and the company's former president Carl Reichel, has been arrested in Boston on these charges, and faces a jail sentence along with at least two additional former employees.

Court documents also show there was a top-down policy at Warner Chilcott to encourage salespeople to push branded drugs to healthcare professionals and convince them more expensive drugs were medically necessary.

The medications involved in the claims are Asacol (mesalamine), Doryx (doxycycline hyclate), Enablex (darifenacin) for urinary incontinence, the hormone Estrace (estriadol) and the contraceptive Loestrin (ethinyl estradiol, norethindrone, ferrous fumarate).

One doctor involved is Rita Luthra, who appeared in court charged with receiving $23,500 in illegal kickback payments from Warner Chilcott and violating the patient privacy act.

The charges claim that doctors were hired as speakers on the company's behalf and paid substantial sums on the condition that prescription numbers stayed high. They were also treated specially at medical educational events that took place at expensive restaurants.

Warner Chilcott also admitted manipulating marketing claims for the osteoporosis drugs Atelvia (risedronate) and Actonel (risedronate sodium) so health insurance funded by federal health programs would authorise prescription payments.

Allergan is currently in early-stage discussions with Pfizer to combine the two companies. 

Article by
Nikhil Patel

4th November 2015

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Jet Off with Maloff Protect

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...